drugset / Trial / NCT04511728

A Study to Evaluate the Efficacy and Safety of HSK3486 in the Induction of General Anesthesia

NCT04511728

Phase 3 Completed 129 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a multi-center, randomized, single-blind, propofol injectable emulsion parallel-controlled Phase III clinical study. A total of patients undergoing elective surgery are intended to be enrolled and randomly assigned to HSK3486 group and propofol group in a 2:1 ratio.

Timeline

Start
2020-11-24
Primary completion
2020-12-31
Completion
2021-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.8 mg/kg
Comparator Propofol Small molecule 5 mg/kg

Indications

No indication recorded.